Evotec SE

General information
Evotec SE
Essener Bogen 7
Manfred Eigen Campus
22419 Hamburg, Hamburg

Contact person: Christian Wojczewski, Chief Executive Officer
Company main phone: +49 (40) 560810
Company main fax:  +49 (40) 56081222
Website:  https://www.evotec.com
Year founded:1993
Source of foundation:Independent foundation
No. of employees: Worldwide:  5055
Corporate description / mission:
Evotec is a life science company with a unique business model that delivers on the mission to discover and develop highly effective therapeutics and make them available to the patients. The company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1999
  • Biotechnology - Therapeutics and Diagnostics
  • Anti-infectives
  • Antibodies
  • Biosimilars
  • Cell therapy
  • Gene therapy
  • Immunotherapy
  • Small molecules
  • Stem cells
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Congenital malformations, deformations and chromosomal abnormalities / medical genetics
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Pregnancy, childbirth and the puerperium / obstetrics
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Business incubation
  • In-licensing
  • Manufacturer
  • Out-licensing
  • R&D
  • Research on contract basis
  • Service company
Customer segments:
  • Large biotech & big pharma
  • Small biotech
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:10
Phase II:3
On the market:2
Description of products:
The company's partnered pipeline' comprises drug candidates initially developed by Evotec, then licensed or transferred to partners for further development; candidates initially developed by Evotec's partners, incorporated into joint research projects where Evotec earns milestone payments or royalties; assets in our co-owned pipeline come from Evotec's portfolio of 20 equity companies.

>250 projects: Partnered, unpartnered, equity, BRIDGEs

Pre clinical: ND
Phase I: 10
Phase II: 3
Phase III: /
On the market: 2
Technology used:
iPSC platform
Financing details
Fiscal year (end of) 2023
Revenues:USD 845.50M
R&D expenses:USD 74.15M
Cash:USD 552.80M
Total liabilities:USD 1'225.43M
No. of shares:177'186'000
Market cap. / valuation:USD 1'743.67M
Collaborations & Clients
Partnering strategy / collaborations:
Evotec’s co-ownership model represents a collaborative and
integrated approach to drug discovery and development. By partnering with pharmaceutical and biotech companies, Evotec aims to leverage shared expertise, resources, and risks to drive the development of innovative therapies. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.

Pharma: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Lilly (Eli Lilly and Company), Merck, Novartis, Pfizer, Sanofi, Takeda
Biotech: Alpine Immune Sciences, Kazia Therapeutics
Non-Profit: US Department of Defense